Tags

Type your tag names separated by a space and hit enter

Past, present and future of pharmacotherapy for obesity.
Clin Investig Arterioscler. 2017 Nov - Dec; 29(6):256-264.CI

Abstract

Conventional treatment for obesity with diet, exercise and bariatric surgery has limitations; thus, it is necessary to have pharmacological tools. In the past, different drugs were marketed that were withdrawn due to safety problems. There are currently 3 drugs approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for obesity therapy (orlistat, combination of bupropion and delayed-release naltrexone and liraglutide) and two more only authorized by FDA (lorcaserin and the combination of phentermine and extended release topiramate). It is recommended to use as a second therapeutic line and its choice should be individualized taking into account multiple aspects such as expected weight loss, route of administration, safety profile and cost. Currently there are several drugs under development that act on different therapeutic targets.

Authors+Show Affiliations

Servicio de Endocrinología y Nutrición, Hospital del Mar de Barcelona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, España. Electronic address: 96002@parcdesalutmar.cat.Servicio de Endocrinología y Nutrición, Hospital del Mar de Barcelona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, España.Servicio de Endocrinología y Nutrición, Hospital del Mar de Barcelona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, España.Servicio de Endocrinología y Nutrición, Hospital del Mar de Barcelona, Barcelona, España.Servicio de Endocrinología y Nutrición, Hospital del Mar de Barcelona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, España.

Pub Type(s)

Journal Article
Review

Language

eng spa

PubMed ID

28935287

Citation

Benaiges, David, et al. "Past, Present and Future of Pharmacotherapy for Obesity." Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis, vol. 29, no. 6, 2017, pp. 256-264.
Benaiges D, Pedro-Botet J, Flores-Le Roux JA, et al. Past, present and future of pharmacotherapy for obesity. Clin Investig Arterioscler. 2017;29(6):256-264.
Benaiges, D., Pedro-Botet, J., Flores-Le Roux, J. A., Climent, E., & Goday, A. (2017). Past, present and future of pharmacotherapy for obesity. Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis, 29(6), 256-264. https://doi.org/10.1016/j.arteri.2017.06.002
Benaiges D, et al. Past, Present and Future of Pharmacotherapy for Obesity. Clin Investig Arterioscler. 2017 Nov - Dec;29(6):256-264. PubMed PMID: 28935287.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Past, present and future of pharmacotherapy for obesity. AU - Benaiges,David, AU - Pedro-Botet,Juan, AU - Flores-Le Roux,Juana A, AU - Climent,Elisenda, AU - Goday,Albert, Y1 - 2017/09/19/ PY - 2017/06/22/received PY - 2017/06/27/accepted PY - 2017/9/25/pubmed PY - 2018/9/7/medline PY - 2017/9/23/entrez KW - Drug treatment KW - Exceso de peso KW - Farmacoterapia KW - Obesidad KW - Obesity KW - Overweight KW - Pharmacotherapy KW - Pérdida de peso KW - Tratamiento con fármacos KW - Weight loss SP - 256 EP - 264 JF - Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis JO - Clin Investig Arterioscler VL - 29 IS - 6 N2 - Conventional treatment for obesity with diet, exercise and bariatric surgery has limitations; thus, it is necessary to have pharmacological tools. In the past, different drugs were marketed that were withdrawn due to safety problems. There are currently 3 drugs approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for obesity therapy (orlistat, combination of bupropion and delayed-release naltrexone and liraglutide) and two more only authorized by FDA (lorcaserin and the combination of phentermine and extended release topiramate). It is recommended to use as a second therapeutic line and its choice should be individualized taking into account multiple aspects such as expected weight loss, route of administration, safety profile and cost. Currently there are several drugs under development that act on different therapeutic targets. SN - 1578-1879 UR - https://www.unboundmedicine.com/medline/citation/28935287/Past_present_and_future_of_pharmacotherapy_for_obesity_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0214-9168(17)30085-2 DB - PRIME DP - Unbound Medicine ER -